BridgeBio Oncology Therapeutics Inc.

BBOT | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.66

-$0.11 (-2.31%)

At close: Sep 21, 2026, 4:00 PM ET

$4.58

-$0.08 (-1.72%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $382.11M

Enterprise Value $150.1M

Beta 0.39

Average Volume 368.86K

Shares Outstanding (Diluted) 80.05K

Shares Change YoY -99.66%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US1079241022

Price Performance

Price Change 1M -48.5%

Price Change 3M -37.9%

Price Change 6M -49.6%

Price Change YTD -62.1%

Price Change 1Y -61.5%

Price Change 3Y -56.2%

Price Change 5Y -56.2%

1M CAGR (ann.) -45.7%

1Y CAGR (ann.) -55.8%

5Y CAGR (ann.) N/A

All-Time CAGR -25.3%

Valuation

PE Ratio -0.01

Forward PE N/A

PEG Ratio 0.00

Forward PEG 0.00

PS Ratio N/A

Forward PS 12.80

PB Ratio 1.16

P/FCF Ratio -1.93

P/Adj. FCF Ratio -1.83

P/OCF Ratio -0.00

EV/Sales N/A

EV/EBIT -0.77

EV/EBITDA -0.77

EV/FCF -0.77

Earnings Yield -15229.6%

FCF Yield -51.9%

Adj. FCF Yield -54.6%

Financial Health

Net Cash $223.2M

Total Debt $2.51M

Cash & Short-Term Investments $225.71M

Total Assets $376.71M

Current Ratio 4.69

Quick Ratio 4.69

Debt / Equity Ratio 0.01

Debt / EBITDA -0.01

Debt / FCF -0.01

OCF / Debt -76.83

Interest Coverage 0.00

Altman Z-Score 1.48

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -5.3%

Returns

Return on Assets -48.3%

Return on Equity -46.9%

Return on Invested Capital -61.1%

Return on Capital Employed -61.2%

Return on Tangible Assets -48.3%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -149.5%

EPS CAGR 5Y N/A

EPS CAGR 10Y N/A

FCF CAGR 3Y -104.1%

FCF CAGR 5Y N/A

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 8

EPS Growth Next 3Y 33.2%

Revenue Growth Next 3Y N/A

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$0.66

EPS Growth Est (next Q) -36.0%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $19

Price Target Upside 307.7%

Cash Flow

Operating Cash Flow $-193.14M

Free Cash Flow $-193.82M

Adj. Free Cash Flow $-203.99M

FCF Per Share -$2,421.06

OCF Per Share -$2,412.60

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-186K

Operating Income $-198.96M

EBITDA $-194.66M

Net Income $-182.11M

EPS (Diluted) -$709.70

Revenue / Employee N/A

Profit / Employee $-2.07M

Employees 88